Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus.

Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ.

J Rheumatol. 2019 Oct;46(10):1309-1315. doi: 10.3899/jrheum.180946. Epub 2019 Feb 1.

PMID:
30709949
2.

A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.

Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A.

Eur J Contracept Reprod Health Care. 2018 Oct;23(5):326-334. doi: 10.1080/13625187.2018.1508650. Epub 2018 Sep 24.

PMID:
30247084
3.

Nutrition Education in Internal Medicine Residency Programs and Predictors of Residents' Dietary Counseling Practices.

Khandelwal S, Zemore SE, Hemmerling A.

J Med Educ Curric Dev. 2018 Mar 21;5:2382120518763360. doi: 10.1177/2382120518763360. eCollection 2018 Jan-Dec.

4.

Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women.

Seidman D, Hemmerling A, Smith-McCune K.

Semin Reprod Med. 2016 May;34(3):159-67. doi: 10.1055/s-0036-1571436. Epub 2016 Mar 8. Review.

PMID:
26956691
5.

Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach.

Young Holt B, Romano J, Manning J, Hemmerling A, Shields W, Vyda L, Lusti-Narasimhan M.

BJOG. 2014 Oct;121 Suppl 5:3-8. doi: 10.1111/1471-0528.12911. No abstract available.

6.

Prioritizing multipurpose prevention technology development and investments using a target product profile.

Romano J, Manning J, Hemmerling A, McGrory E, Holt BY.

Antiviral Res. 2013 Dec;100 Suppl:S32-8. doi: 10.1016/j.antiviral.2013.09.016. Epub 2013 Nov 1.

PMID:
24188707
7.

Developing multipurpose reproductive health technologies: an integrated strategy.

Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B.

AIDS Res Treat. 2013;2013:790154. doi: 10.1155/2013/790154. Epub 2013 Feb 28.

8.

Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations.

Hemmerling A, Harrison WG, Brown JM, Moscicki B, Oziemkowska M, Bukusi EA, Cohen CR.

Sex Transm Dis. 2012 Sep;39(9):710-2. doi: 10.1097/OLQ.0b013e3182641f08.

9.

Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05.

Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, Fredricks DN, Cohen CR.

Sex Transm Dis. 2011 Nov;38(11):1020-7. doi: 10.1097/OLQ.0b013e3182267ac4.

10.

Probiotics: the potential for a live microbicide to prevent HIV.

Hemmerling A, Cohen CR.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e98-101. doi: 10.1097/QAI.0b013e3182056ad9. No abstract available.

11.

Women front and center: the opportunities of involving women in participatory health research worldwide.

Decker M, Hemmerling A, Lankoande F.

J Womens Health (Larchmt). 2010 Nov;19(11):2109-14. doi: 10.1089/jwh.2010.2059. Epub 2010 Sep 21.

PMID:
20858061
12.

Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis.

Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Foster-Rosales A, Cohen CR.

Sex Transm Dis. 2010 Dec;37(12):745-50. doi: 10.1097/OLQ.0b013e3181e50026.

PMID:
20644497
13.

Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.

Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR.

Sex Transm Dis. 2009 Sep;36(9):564-9. doi: 10.1097/OLQ.0b013e3181a74924.

14.

Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally.

Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA.

J Womens Health (Larchmt). 2007 Sep;16(7):1041-51.

PMID:
17903081
15.

The worldwide burden of postpartum haemorrhage: Policy development where inaction is lethal.

Potts M, Hemmerling A.

Int J Gynaecol Obstet. 2006 Nov;94 Suppl 2:S116-21.

PMID:
17161133
16.

The safety of misoprostol.

Hemmerling A.

Int J Gynaecol Obstet. 2006 Nov;94 Suppl 2:S149-S150. doi: 10.1016/S0020-7292(06)60019-2. No abstract available.

PMID:
29644678
17.

Drugs and drug administration in extreme environments.

Küpper TE, Schraut B, Rieke B, Hemmerling AV, Schöffl V, Steffgen J.

J Travel Med. 2006 Jan-Feb;13(1):35-47. Review.

18.

Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association.

Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H, Gonzalez WV, Cordero M, Calderon V.

BJOG. 2005 Sep;112(9):1291-6.

19.

Emotional impact and acceptability of medical abortion with mifepristone: a German experience.

Hemmerling A, Siedentopf F, Kentenich H.

J Psychosom Obstet Gynaecol. 2005 Mar;26(1):23-31.

PMID:
15962719
20.

Couples becoming parents: something special after IVF?

Ulrich D, Gagel DE, Hemmerling A, Pastor VS, Kentenich H.

J Psychosom Obstet Gynaecol. 2004 Jun;25(2):99-113.

PMID:
15715033
21.

[Lymphangiomatosis as the cause of therapy refractory chylothorax and ascites].

Hemmerling A, Kemnitz J.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1996 Sep;31(7):434-7. German.

PMID:
8991474
22.

Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency.

Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA.

Clin Nephrol. 1996 Mar;45(3):180-2.

PMID:
8706359
23.

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products.

Wagner D, Wagenbreth I, Stachan-Kunstyr R, Thoma HA, Hemmerling AE, Flik J.

Clin Investig. 1994 May;72(5):350-2.

PMID:
8086768
24.

Frequency and clinical implications of recurrent carotid artery stenosis.

Sandmann W, Kniemeyer HW, Hemmerling A.

Ann Chir Gynaecol. 1992;81(2):231-5. No abstract available.

PMID:
1622088

Supplemental Content

Loading ...
Support Center